Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade D 43.0 0.49% 0.21
RARE closed up 0.49 percent on Friday, December 6, 2019, on 65 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical RARE trend table...

Date Alert Name Type % Chg
Doji - Bearish? Reversal 0.00%
Upper Bollinger Band Walk Strength 0.00%
Weak + Overbought Other 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Upper Bollinger Band Walk Strength 0.49%
Older signals for RARE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Rare Diseases Enzyme Replacement Therapy Biologics Rare And Ultra Rare Diseases

Is RARE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 74.5
52 Week Low 35.41
Average Volume 519,646
200-Day Moving Average 55.43
50-Day Moving Average 40.62
20-Day Moving Average 38.97
10-Day Moving Average 40.45
Average True Range 1.58
ADX 29.54
+DI 24.71
-DI 14.56
Chandelier Exit (Long, 3 ATRs ) 38.90
Chandelier Exit (Short, 3 ATRs ) 40.14
Upper Bollinger Band 42.99
Lower Bollinger Band 34.94
Percent B (%b) 1.0
BandWidth 20.66
MACD Line 0.49
MACD Signal Line -0.26
MACD Histogram 0.7514
Fundamentals Value
Market Cap 1.83 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -6.38
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.70
Resistance 3 (R3) 44.72 44.17 44.41
Resistance 2 (R2) 44.17 43.74 44.16 44.32
Resistance 1 (R1) 43.59 43.47 43.32 43.57 44.22
Pivot Point 43.04 43.04 42.91 43.03 43.04
Support 1 (S1) 42.46 42.61 42.19 42.44 41.78
Support 2 (S2) 41.91 42.34 41.90 41.68
Support 3 (S3) 41.33 41.91 41.59
Support 4 (S4) 41.31